Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer
Recruiting · NCT04612907 · Interventional (participants receive a specific treatment) · Lead sponsor: Umeå University
View the official record on ClinicalTrials.gov →Interventions studied
Moderate hypo-fractionationUltra-hypo-fractionation
What this trial is about
de Novo metastatic prostate cancer with limited metastatic spread benefits from local radiotherapy to the prostate. Two different fractionation schedules will be tested.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Signed Informed Consent
- Histological confirmed prostate cancer
- Indication for early palliative radiation therapy of low burden metastatic prostate cancer. Low burden as defined by modified CHAARTED trial criteria to maximum 4 skeletal mets at any site and/or any number of lymph nodes
- baseline E-PROM
Exclusion criteria
- High burden metastatic prostate cancer including all with visceral mets.
- Unable to comply with study procedures.
- Other diseases or medication that will put the patient at risk for more toxicity from radiotherapy
- Radiation treatment start later than nine months after the prostate cancer diagnosis.
- Severe micturition problems, IPSS \> 20 ( International Prostate Symptom Score)
Where it is running
1 location listed.
- Cancercenter University hospital of Umeå - Umeå, Sweden